Form 4: Relmada Therapeutics Officer Chuck Ence Acquires Additional Shares
SEC Form 4 Filing
Chuck Ence, an officer at Relmada Therapeutics, recently purchased 228,961 shares of common stock at a weighted average price of $0.4513 per share.
Summary
- On May 16, 2025, Chuck Ence, an officer of Relmada Therapeutics, Inc., acquired 228,961 shares of common stock.
- The shares were purchased through multiple open market transactions.
- The weighted average price paid per share was $0.4513, with individual prices ranging from $0.401 to $0.4892.
- Following the transaction, Mr. Ence directly owns 267,931 shares of Relmada Therapeutics.
Sentiment
Score: 5
Explanation: Neutral sentiment. This is a routine disclosure of an officer's stock purchase. The purchase itself could be interpreted as a positive signal, but the filing is simply a factual report.
Positives
- An officer increasing their stake in the company could be seen as a positive signal.
Industry Context
This filing reflects insider trading activity, which is routinely monitored by investors to gauge management's sentiment and confidence in the company's prospects. It is a common practice and a normal part of the stock market.
Stakeholder Impact
- The purchase of shares by an officer may increase investor confidence.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date of transaction: Chuck Ence purchased shares of RLMD. |
| 05/20/2025 | Date of Form 4 filing. |
Keywords
Relmada Therapeutics, RLMD, Chuck Ence, stock purchase, Form 4, officer, beneficial ownership, open market transactions
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.